首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1498582

基因检测市场规模、份额、成长分析、按产品类型、按技术、按测试类型、按方法、按最终用户、按地区 - 行业预测，2024-2031 年

Genetic Testing Market Size, Share, Growth Analysis, By Product, By Technology, By Testing Type, By Methods, By End-User, By Region - Industry Forecast 2024-2031

出版日期: 2024年06月16日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年基因检测市场规模估值为60.8亿美元，从2023年的74.2亿美元增长到2031年的364亿美元，预计在预测期内（2024-2031年）将以22%的复合年增长率增长。

基因检测在癌症治疗中变得越来越重要，包括风险评估、筛检、降低风险和治疗策略。定序技术的进步和成本的降低已将基因检测推入肿瘤学的主流。流行病学研究不断揭示与各种基因相关的癌症风险，而指南则为 40 多个基因的致病性变异 (PV) 提供筛检和预防建议。种系检测结果可能会影响治疗决策，例如 PARP 抑制剂正在核准用于治疗 BRCA1/2 基因突变的乳癌、胰臟癌、摄护腺癌和卵巢。国家医学图书馆根据分析有效性、临床有效性和临床效用评估基因测试，确保稳健的评估标准。在全球范围内，儘管主要零售商提供的直接面向消费者的套件基因检测存在监管复杂性和成本等挑战，但由于技术创新、疾病意识增强和人口老龄化，市场正在扩大。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 义大利
- 英国
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Illumina, Inc.（US）
Thermo Fisher Scientific, Inc.（US）
Qiagen NV（Netherlands）
Myriad Genetics, Inc.（US）
Invitae Corporation（US）
BGI Group（China）
Eurofins Scientific SE（Europe）
F. Hoffmann-La Roche AG（Switzerland）
PerkinElmer, Inc.（US）
Becton, Dickinson and Company（US）
Agilent Technologies, Inc.（US）
Bio-Rad Laboratories, Inc.（US）
23andMe, Inc.（US）
Ancestry.com LLC（US）
GeneDx, Inc.（US）
Counsyl, Inc.（US）
Natera, Inc.（US）
Veracyte, Inc.（US）
Guardant Health, Inc.（US）
Caris Life Sciences.（US）

简介目录

Product Code: SQMIG35H2074

Genetic Testing Market size was valued at USD 6.08 billion in 2022 and is poised to grow from USD 7.42 billion in 2023 to USD 36.40 billion by 2031, growing at a CAGR of 22% in the forecast period (2024-2031).

Genetic testing in cancer care is increasingly pivotal, encompassing risk assessment, screening, risk mitigation, and treatment strategies. Advances in sequencing technologies and reduced costs have propelled genetic testing into mainstream oncology. Epidemiological studies continually uncover cancer risks associated with various genes, while guidelines provide screening and prevention recommendations for pathogenic variants (PVs) in over 40 genes. Germline test results increasingly influence treatment decisions, exemplified by the approval of PARP inhibitors for breast, pancreatic, prostate, and ovarian cancers in individuals with BRCA1/2 mutations. The National Library of Medicine evaluates genetic tests based on analytical validity, clinical validity, and clinical utility, ensuring robust assessment standards. Globally, the market is expanding due to technological innovations, heightened disease awareness, and ageing populations, despite challenges like regulatory complexities and costs associated with direct-to-consumer genetic testing kits available from major retailers.

Top-down and bottom-up approaches were used to estimate and validate the size of the Genetic Testing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Genetic Testing Market Segmental Analysis

The genetic testing market is segmented based on testing type, technology, application, and region. In terms of products, the market is segmented into consumables, equipment, and software and services. Based on technology, the market is segmented into next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, chemiluminescence immunoassay, and others. Based on testing type, the market is segmented into predictive testing and presymptomatic testing, carrier testing, prenatal and newborn testing, preimplantation testing, diagnostic testing, pharmacogenomic testing, nutrigenomic testing, and forensic testing. Based on methods, the market is segmented into molecular genetic testing, cytogenetic testing, chromosomal genetic testing, biochemical genetic testing, and others. Based on end users, the market is segmented into hospitals, clinical laboratories, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Genetic Testing Market

The burgeoning growth of the global genetic testing market is poised to be significantly bolstered by the rising prevalence of genetic and rare disorders worldwide. An illustrative example is the European Union, where approximately 36 million people, exceeding the population of New York City, contend with rare diseases. The EU confronts over 6000 distinct rare diseases, underscoring the complex healthcare landscape. Notably, 80% of these conditions stem from genetic factors, with 70% manifesting in childhood, highlighting the urgent need for early detection and intervention measures. This scenario emphasizes the pivotal role of genetic testing in addressing these challenges and improving patient outcomes through timely identification and management strategies.

Restraints in the Genetic Testing Market

An anticipated challenge that could impede market growth is the high cost of genetic testing. According to the National Library of Medicine, prices for genetic tests vary widely, ranging from less than $100 to over $2,000, depending on their complexity and breadth. Additional costs may arise when multiple tests are needed or when testing extends to multiple family members to achieve meaningful clinical outcomes. Therefore, the substantial financial investment required for these tests presents a significant barrier to widespread market accessibility and adoption, potentially limiting the reach of genetic testing technologies to broader populations and healthcare applications.

Market Trends of the Genetic Testing Market

Personalized medicine is transforming healthcare by utilizing an individual's genetic makeup to inform decisions on disease prevention, diagnosis, and treatment. This approach customizes medical interventions to match each patient's biological characteristics, leading to significant cost efficiencies in healthcare delivery. By identifying genetic markers influencing drug reactions and treatment outcomes, therapies can be optimized for better safety and effectiveness. This trend is anticipated to persist and evolve in the coming years, promising a future where healthcare interventions are increasingly tailored to the unique genetic profiles of patients, thereby enhancing overall health outcomes and reducing unnecessary medical expenses.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Supply Chain Analysis
Start-up Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Market Attractive Index
Degree of Competition

Genetic Testing Market by Product

Market Overview
Consumables
Equipment
Software and Services

Genetic Testing Market by Technology

Market Overview
Next-generation Sequencing
Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Chemiluminescence Immunoassay
Others

Genetic Testing Market by Testing Type

Market Overview
Predictive Testing and Presymptomatic Testing
Carrier Testing
Prenatal and Newborn Testing
Preimplantation Testing
Diagnostic Testing
Pharmacogenomic Testing
Nutrigenomic Testing
Forensic Testing

Genetic Testing Market by Methods

Market Overview
Molecular Genetic Testing
Chromosomal Genetic Testing
Biochemical Genetic Testing
Others

Genetic Testing Market by End Users

Market Overview
Hospitals
Clinical Laboratories
Others

Genetic Testing Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- Italy
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Invitae Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BGI Group (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific SE (Europe)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
23andMe, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ancestry.com LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GeneDx, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Counsyl, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Veracyte, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Caris Life Sciences. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments